Study provides valuable insights into the DCB-only strategy for left main coronary artery disease

Sanna Uskela et al., at North Karelia Central Hospital-Heart Center, Finland, conducted a retrospective single-center registry study that focused on the use of drug-coated balloon (DCB)-only strategy for treating de novo left main coronary artery disease.

Straumann Group 2023 full-year results webcast – Biotech Investments

Straumann Holding AG / Key word(s): Annual Results/Miscellaneous Invitation: Straumann Group 2023 full-year results webcast 15.02.2024 / 13:26 CET/CEST Date: Tuesday, February 27th, 2024 Time:

February 16, 2024

Higher Steroid Dose for ICI Toxicity Harms Cancer Survival, Analysis Suggests

Higher peak doses of corticosteroids to counter the immune-related adverse effects (irAEs) of immune checkpoint inhibitor (ICI) combination therapy had a significant association with worse

August 20, 2024

RUFY1-RET fusion identified as mechanism of resistance to lorlatinib in lung cancer

A new case report was published in Volume 16 of Oncotarget on February 5, 2025, titled “Acquired RUFY1-RET rearrangement as a mechanism of resistance to

February 6, 2025

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.